Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    23959519 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
Condition: Chronic Fatigue Syndrome
Intervention: Drug: valganciclovir

Study has passed its completion date and status has not been verified in more than two years.